The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways1-Reference-Cited by-同舟云学术

The Prostate Specific Membrane Antigen Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways1

Published:2009-02-26 Issue:2 Volume:4 Page:e4608
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Colombatti Marco,Grasso Silvia,Porzia Alessandra,Fracasso Giulio,Scupoli Maria Teresa,Cingarlini Sara,Poffe Ornella,Naim Hassan Y.,Heine Martin,Tridente Giuseppe,Mainiero Fabrizio,Ramarli Dunia

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference34 articles.

1. The paradigm of IL-6: from basic science to medicine.;T Naka;Arthritis Res,2002

2. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.;M Trikha;Clin Cancer Res,2003

3. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.;CB Siegall;Cancer Res,1990

4. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.;A Hobisch;J Pathol,2000

5. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.;HL Adler;J Urol,1999

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer;Cancer Cell International;2023-10-30

2. Baseline PSMA‐PET/CT as a predictor of PSA persistence following radical prostatectomy in high‐risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy;The Prostate;2023-05-10

3. D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer;ACS Applied Bio Materials;2023-02-09

4. CCL5/CCR5 Axis in Cancer;Cytokine and Chemokine Networks in Cancer;2023

5. Human blood biocompatibility and immunogenicity of scFvD2B PEGylated gold nanoparticles;Nanotechnology;2022-05-11